TSO3 Appoints New Chief Science Officer

TSO3 (TSX:TOS) announced the appointment of Dr. Bradley J. Catalone as the company’s new chief science officer.

As quoted in the press release:

Dr. Catalone has extensive knowledge of medical devices and the sterilization industry, having held significant roles within Olympus Corporation of the Americas Inc., including as Infection Control Manager, Director of Research, as well as Director of Clinical Affairs.  Most recently, Dr. Catalone held the position of Vice President of Laboratory Services at Alcami Corporation with responsibility for drug development and analytical testing services.  Dr. Catalone holds a Ph.D. in Microbiology and Immunology from Penn State College of MedicineHershey, PA and an MBA. in Business Administration from the Pennsylvania State University.

“I am very pleased to welcome Brad to the TSO3 organization” stated R.M. (Ric) Rumble TSO3‘s President and CEO.  “Brad brings fifteen years of professional experience with increased accountability and responsibility within our industry. He is a strong advocate for patient safety and has directly championed improvements in device reprocessing.”

Click here to read the full press release.

Get the Latest Medical Device Investing Stock Information

Get the latest information about companies associated with Medical Device Investing delivered directly to your inbox.

Medical Device

By selecting company or companies above, you are giving consent to receive email from those companies. And remember you can unsubscribe at any time.

Comments

Leave a Reply